About Day Zero Diagnostics
Day Zero Diagnostics is a company based in Boston (United States) founded in 2016. Day Zero Diagnostics has raised $48.6 million across 10 funding rounds from investors including NIH, BD and CARB-X. The company has 48 employees as of December 31, 2024. Day Zero Diagnostics offers products and services including epiXact® Service, Whole Genome Sequencing Diagnostics, and Computational Diagnostic Algorithms. Day Zero Diagnostics operates in a competitive market with competitors including Cepheid, Prenetics, Karius, OpGen and Clear Labs, among others.
- Headquarter Boston, United States
- Employees 48 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Day Zero Diagnostics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$48.6 M (USD)
in 10 rounds
-
Latest Funding Round
$16 M (USD), Series B
Sep 20, 2023
-
Investors
NIH
& 10 more
-
Employee Count
48
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Day Zero Diagnostics
Day Zero Diagnostics offers a comprehensive portfolio of products and services, including epiXact® Service, Whole Genome Sequencing Diagnostics, and Computational Diagnostic Algorithms.
Provides rapid genome sequencing for pathogen relatedness in hospitals.
Offers quick ID and AMR profiling for infectious diseases treatment.
Delivers algorithms for analyzing genomic data in disease diagnostics.
People of Day Zero Diagnostics
Unlock access to complete
Funding Insights of Day Zero Diagnostics
Day Zero Diagnostics has successfully raised a total of $48.6M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $16 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Day Zero Diagnostics
Day Zero Diagnostics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, BD and CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences venture fund is operated with global reach.
|
Locked | Locked | Locked | |
|
Tech & Life-Sciences focused VC Firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early stage healthcare startups
|
Locked | Locked | Locked |
Investor details for Day Zero Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Day Zero Diagnostics
Investment portfolio details for Day Zero Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Day Zero Diagnostics
Detailed financials for Day Zero Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Day Zero Diagnostics Comparisons
Peer comparison for Day Zero Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Day Zero Diagnostics
Day Zero Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Prenetics, Karius, OpGen and Clear Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Food safety technologies are provided for pathogen identification.
|
Detailed competitors of Day Zero Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Day Zero Diagnostics
Complete news archive for Day Zero Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Day Zero Diagnostics
Day Zero Diagnostics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Day Zero Diagnostics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Day Zero Diagnostics is a funded company, having raised a total of $48.6M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Day Zero Diagnostics is 48.
Day Zero Diagnostics was founded in 2016 in Boston, United States, within the health technology sector. Diagnostic solutions based on machine learning and genomics are provided for infectious diseases. Whole-genome sequencing is utilized in assays such as Blood2Bac and BacDetect to identify infecting bacterial species and drug resistance. Operations focus on advancing rapid diagnostics for clinical applications.
Day Zero Diagnostics's top competitors include Cepheid, Prenetics and Clear Labs.
Day Zero Diagnostics offers epiXact® Service, Whole Genome Sequencing Diagnostics, and Computational Diagnostic Algorithms.
Day Zero Diagnostics has 11 investors. Key investors include NIH, BD, CARB-X, Sands Capital, and Panacea Venture.